Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 05 2022
25 05 2022
Historique:
received:
20
11
2021
accepted:
17
05
2022
entrez:
25
5
2022
pubmed:
26
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small-cell lung cancer (NSCLC) might depend on the presence of emphysema, but this association is not established. We aimed to investigate if quantitively and automatically measuring emphysema can predict the effect of ICIs. We retrospectively analyzed 56 patients with NSCLC who underwent immunotherapy at our hospital. We used the Goddard scoring system (GS) to evaluate the severity of emphysema on baseline CT scans using three-dimensional image analysis software. The emphysema group (GS ≥ 1) showed better progression-free survival (PFS) than the non-emphysema group (GS = 0) (6.5 vs. 2.3 months, respectively, p < 0.01). Multivariate analyses revealed that good performance status, GS of ≥ 1, and high expression of PD-L1 were independently associated with better PFS, while smoking status was not. In conclusion, quantitative evaluation of emphysema can be an objective parameter for predicting the therapeutic effects of ICIs in patients with NSCLC. Our findings can be used to generate hypotheses for future studies.
Identifiants
pubmed: 35614345
doi: 10.1038/s41598-022-13131-2
pii: 10.1038/s41598-022-13131-2
pmc: PMC9133115
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8881Informations de copyright
© 2022. The Author(s).
Références
J Thorac Dis. 2016 Aug;8(8):1966-73
pubmed: 27621848
Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940
pubmed: 29518341
J Immunother Cancer. 2019 Feb 27;7(1):57
pubmed: 30813970
Clin Radiol. 1982 Jul;33(4):379-87
pubmed: 7083738
Immunotherapy. 2019 Feb;11(3):189-199
pubmed: 30730276
Clin Lung Cancer. 2020 Mar;21(2):106-113.e5
pubmed: 31992521
Sci Rep. 2019 Feb 21;9(1):2447
pubmed: 30792455
Thorax. 2016 Jul;71(7):624-32
pubmed: 27048196
In Vivo. 2021 Jan-Feb;35(1):467-474
pubmed: 33402498
JTO Clin Res Rep. 2020 Mar 04;1(2):100020
pubmed: 34589927
Radiat Oncol. 2019 Sep 11;14(1):166
pubmed: 31511012
Lung Cancer. 2012 Jul;77(1):58-63
pubmed: 22437042
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Lung Cancer. 2020 Sep;147:12-20
pubmed: 32652369
J Immunol. 2018 Sep 1;201(5):1558-1569
pubmed: 30037849
J Thorac Dis. 2018 Feb;10(2):874-881
pubmed: 29607160
Am J Respir Crit Care Med. 2018 Feb 1;197(3):325-336
pubmed: 28934595